611 related articles for article (PubMed ID: 15384126)
1. Impact of the motor complications of Parkinson's disease on the quality of life.
Chapuis S; Ouchchane L; Metz O; Gerbaud L; Durif F
Mov Disord; 2005 Feb; 20(2):224-30. PubMed ID: 15384126
[TBL] [Abstract][Full Text] [Related]
2. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
3. Influence of motor symptoms upon the quality of life of patients with Parkinson's disease.
Gómez-Esteban JC; Zarranz JJ; Lezcano E; Tijero B; Luna A; Velasco F; Rouco I; Garamendi I
Eur Neurol; 2007; 57(3):161-5. PubMed ID: 17213723
[TBL] [Abstract][Full Text] [Related]
4. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Marras C; Lang A; Krahn M; Tomlinson G; Naglie G;
Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356
[TBL] [Abstract][Full Text] [Related]
6. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
Maurel F; Lilliu H; Le Pen C
Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
[TBL] [Abstract][Full Text] [Related]
7. Independent validation of SCOPA-psychosocial and metric properties of the PDQ-39 Brazilian version.
Carod-Artal FJ; Martinez-Martin P; Vargas AP
Mov Disord; 2007 Jan; 22(1):91-8. PubMed ID: 17094102
[TBL] [Abstract][Full Text] [Related]
8. [Validation of the Japanese version of the Parkinson's Disease Questionnaire].
Kohmoto J; Ohbu S; Nagaoka M; Suzukamo Y; Kihira T; Mizuno Y; Ito YM; Hith M; Yamaguchi T; Ohashi Y; Fukuhara S; Kondo T
Rinsho Shinkeigaku; 2003 Mar; 43(3):71-6. PubMed ID: 12820553
[TBL] [Abstract][Full Text] [Related]
9. Psychometric characteristics of the Parkinson's disease questionnaire (PDQ-39)--Ecuadorian version.
Martínez-Martín P; Serrano-Dueñas M; Vaca-Baquero V
Parkinsonism Relat Disord; 2005 Aug; 11(5):297-304. PubMed ID: 15886043
[TBL] [Abstract][Full Text] [Related]
10. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
12. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.
Stacy M; Bowron A; Guttman M; Hauser R; Hughes K; Larsen JP; LeWitt P; Oertel W; Quinn N; Sethi K; Stocchi F
Mov Disord; 2005 Jun; 20(6):726-33. PubMed ID: 15719426
[TBL] [Abstract][Full Text] [Related]
13. Freezing of gait affects quality of life of peoples with Parkinson's disease beyond its relationships with mobility and gait.
Moore O; Peretz C; Giladi N
Mov Disord; 2007 Nov; 22(15):2192-5. PubMed ID: 17712856
[TBL] [Abstract][Full Text] [Related]
14. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
Antonini A; Isaias IU; Canesi M; Zibetti M; Mancini F; Manfredi L; Dal Fante M; Lopiano L; Pezzoli G
Mov Disord; 2007 Jun; 22(8):1145-9. PubMed ID: 17661426
[TBL] [Abstract][Full Text] [Related]
15. [Assessing quality of life in Parkinson's disease using the PDQ-39. A pilot study].
Martínez-Martín P; Frades Payo B; Fontán Tirado C; Martínez Sarriés FJ; Guerrero MT; del Ser Quijano T
Neurologia; 1997 Feb; 12(2):56-60. PubMed ID: 9147452
[TBL] [Abstract][Full Text] [Related]
16. [Neuropsychiatric problems in patients with Parkinson's disease].
Zhou MZ; Liu ZG; Gan J; Chen W; Lu LX; Wu JY
Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(21):1442-5. PubMed ID: 18953846
[TBL] [Abstract][Full Text] [Related]
17. Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life.
Grosset KA; Grosset DG
Mov Disord; 2005 May; 20(5):616-9. PubMed ID: 15719417
[TBL] [Abstract][Full Text] [Related]
18. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease.
Santos-García D; de la Fuente-Fernández R
J Neurol Sci; 2013 Sep; 332(1-2):136-40. PubMed ID: 23890935
[TBL] [Abstract][Full Text] [Related]
19. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
[TBL] [Abstract][Full Text] [Related]
20. [Validation of the French language version of the Parkinson's Disease Questionnaire - PDQ-39].
Auquier P; Sapin C; Ziegler M; Tison F; Destée A; Dubois B; Allicar MP; Thibault JL; Jenkinson C; Peto V
Rev Neurol (Paris); 2002 Jan; 158(1):41-50. PubMed ID: 11938321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
